Status:
COMPLETED
Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Overweight
Obesity
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will look at the change in body weight in people taking NNC0174-0833, liraglutide and "dummy" medicine, from the start to the end of the study. As well as taking the medicine, participants ...
Eligibility Criteria
Inclusion
- 18 years or older at the time of signing the informed consent.
- Female subject of non-childbearing potential or Male subject who is surgically sterilised (vasectomy) or who is willing to use adequate contraceptive methods (as required by local regulation or practice) throughout the trial (until 'end of trial').
- BMI equal to 30.0 kg/m\^2 or greater or BMI equal to 27.0 kg/m\^2 or greater with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension or dyslipidaemia (to be assessed at the investigator's discretion).
Exclusion
- HbA1c equal to 48 mmol/mol (6.5 percentage) or greater as measured by the central laboratory at screening.
- A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days prior to screening irrespective of medical records.
Key Trial Info
Start Date :
March 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 25 2021
Estimated Enrollment :
706 Patients enrolled
Trial Details
Trial ID
NCT03856047
Start Date
March 1 2019
End Date
March 25 2021
Last Update
July 5 2024
Active Locations (54)
Enter a location and click search to find clinical trials sorted by distance.
1
Anaheim Clinical Trials, LLC
Anaheim, California, United States, 92801
2
Encompass Clinical Research
Spring Valley, California, United States, 91978
3
Nature Coast Clinical Research
Crystal River, Florida, United States, 34429
4
Jacksonville Center For Clinical Research
Jacksonville, Florida, United States, 32216